Bio-Path Holdings, Inc. - Common Stock (BPTH)

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort

Advancing Multiple Programs in Areas of Significant Unmet Medical Need

Bio-Path Holdings, Inc. (NASDAQBPTH) shares are surging Thursday following the company's announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2 diabetes. Here's what you need to know.

Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 Diabetes

Dallas, Texas--(Newsfile Corp. - December 13, 2024) - Bio-Path Holdings, Inc. (NASDAQBPTH): Stonegate Capital Partners Updates Coverage on Bio-Path...

Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance

Expands DNAbilize® Technology Beyond Oncology into Obesity

HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQBPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview.

HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQBPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of an aggregate of 4,597,702 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 6,407,657 shares of common stock and short-term series B warrants to purchase up to 6,407,657 shares of common stock at a purchase price of $0.87 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement. The series A warrants and short-term series B warrants have an exercise price of $1.00 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the “Stockholder Approval Date”). The series A warrants will expire five years from the Stockholder Approval Date and the short-term series B warrants will expire twenty-four months from the Stockholder Approval Date.